Clinical Trial Detail

NCT ID NCT02710396
Title Genetic Predictors of Benefit to Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University

head and neck cancer

bladder urothelial carcinoma

esophagus squamous cell carcinoma

lung non-small cell carcinoma


Carboplatin + Pembrolizumab + Pemetrexed Disodium


Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST